Search Results

You are looking at 101 - 110 of 2,748 items for :

  • Refine by Access: All x
Clear All
Full access

Cost-Effectiveness of Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer

Bin Wu and Lizheng Shi

gemcitabine-based chemotherapy, has significantly improved the outcome of patients with metastatic pancreatic cancer (MPC), increasing median overall survival (OS) to 8 to 12 months. 3 However, therapeutic options for MPC are still limited and the prognosis

Full access

Randomized Trial of a Smartphone Mobile App to Improve Symptoms and Adherence to Oral Therapy for Cancer

Joseph A. Greer, Jamie M. Jacobs, Nicole Pensak, Lauren E. Nisotel, Joel N. Fishbein, James J. MacDonald, Molly E. Ream, Emily A. Walsh, Joanne Buzaglo, Alona Muzikansky, Inga T. Lennes, Steven A. Safren, William F. Pirl, and Jennifer S. Temel

survival. 10 – 14 Despite its importance for optimal outcomes, adherence to these medications varies widely, with rates ranging from as high as 100% to <50%. 15 – 18 A variety of patient-, clinician-, treatment-, and healthcare system–related factors are

Full access

Development of a Strategic Initiative at MD Anderson Cancer Center to Improve Outcomes in Immune-Related Adverse Events

Sarah E. Fayle, Nicolas L. Palaskas, Bilal A. Siddiqui, Jennifer L. McQuade, Jamie S. Lin, Sumit K. Subudhi, Anisha B. Patel, Robert R. Jenq, Amishi Y. Shah, Amy R. Spelman, Mianen Sun, Bettina H. Marble, and Yinghong Wang

Divisions of Internal Medicine and Cancer Medicine to standardize and expedite irAE diagnosis and management, disseminate best practices, and facilitate IOTOX research to improve patient outcomes. Rationale for IOTOX Initiative and Working Group

Full access

HSR19-112: Qualitative Development of a Patient-Reported Outcome Measure of Symptom Burden in Breast Cancer

Meagan S. Whisenant, Faith A. Strunk, Debasish Tripathy, and Loretta A. Williams

Background: The use of disease-specific patient-reported outcomes (PROs) is critical for facilitating individualized symptom monitoring and improving cancer patient outcomes. The MD Anderson Symptom Inventory (MDASI) is a PRO measure of symptom

Full access

HSR19-082: Epidemiological Findings and Outcomes in Non-Small Cell Lung Cancer Patients with Exon 20 Insertion Mutations: A Meta-Analysis

Victoria Crossland, Aaron Galaznik, Huamao M. Lin, Dimitrios Tomaras, Shan Ashton Garib, Shuanglian Li, Hui Huang, and Anna Forsythe

and outcome data for the uncommon EGFR exon 20 insertion mutation. Methods: An SLR was performed on August 7, 2018 following the Preferred Reporting Item for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, using the Population, Intervention

Full access

Re-Engage: A Novel Nurse-Led Program for Survivors of Childhood Cancer Who Are Disengaged From Cancer-Related Care

Christina Signorelli, Claire E. Wakefield, Karen A. Johnston, Joanna E. Fardell, Jordana K McLoone, Mary-Ellen E. Brierley, Maria Schaffer, Elysia Thornton-Benko, Afaf Girgis, W. Hamish Wallace, Richard J. Cohn, and on behalf of the BSU Implementation Group*

increasingly recognized as key health professionals in survivorship care delivery, with preliminary evidence suggesting that nurse-led care is safe, acceptable, and feasible. 7 Specialized nurse practitioners have the potential to optimize patient outcomes by

Full access

Outcomes and Predictors of 28-Day Mortality in Patients With Hematologic Malignancies and Septic Shock Defined by Sepsis-3 Criteria

Nirmala K. Manjappachar, John A. Cuenca, Claudia M. Ramírez, Mike Hernandez, Peyton Martin, Maria P. Reyes, Alba J. Heatter, Cristina Gutierrez, Nisha Rathi, Charles L. Sprung, Kristen J. Price, and Joseph L. Nates

included small cohorts or were spread over long periods, leading to time bias. 5 , 15 , 16 In other studies, severe sepsis and septic shock are reported together. 5 , 14 This article reports on the short-term outcomes and the independent predictors of 28

Full access

Neoadjuvant Radiotherapy After (m)FOLFIRINOX for Borderline Resectable Pancreatic Adenocarcinoma: A TAPS Consortium Study

Quisette P. Janssen, Jacob L. van Dam, Laura R. Prakash, Deesje Doppenberg, Christopher H. Crane, Casper H.J. van Eijck, Susannah G. Ellsworth, William R. Jarnagin, Eileen M. O’Reilly, Alessandro Paniccia, Marsha Reyngold, Marc G. Besselink, Matthew H.G. Katz, Ching-Wei D. Tzeng, Amer H. Zureikat, Bas Groot Koerkamp, Alice C. Wei, and for the Trans-Atlantic Pancreatic Surgery (TAPS) Consortium

pathologic outcomes were collected locally and merged after deidentification. OS was defined from date of tissue diagnosis to date of death, with censoring at the date of last follow-up for patients with no event. The date of final analysis for the cohort was

Full access

Biomarker Testing, Treatment, and Outcomes in Patients With Advanced/Metastatic Non–Small Cell Lung Cancer Using a Real-World Database

Naleen Raj Bhandari, Lisa M. Hess, Dan He, and Patrick Peterson

might not be treated in a way concordant with their test result and treatment guidelines, and a limited number of studies have investigated this in association with eventual survival outcomes. A study based on administrative claims data from 2010 to 2014

Full access

Representation and Outcomes of Older Adults in Practice-Changing Oncology Trials in the Era of Novel Therapies: A Guideline Appraisal

Ronald Chow, Daniel E. Lage, Grant R. Williams, Mina S. Sedrak, Joseph A. Greer, Jennifer S. Temel, and Ryan D. Nipp

that older adults represent less than one-third of cancer clinical trial participants. Moreover, according to a recent meta-analysis of >150 clinical trials, only between 40% and 70% of clinical trials reported on the outcomes of older adult subgroups